ClinicalTrials.gg
CompletedNCT05633563CACTuS - TMZUpdated Apr 25, 2024

The Effect of Trimetazidine on Mitochondrial Function, Myocardial Performance, and Invasive Hemodynamics in Patients Diagnosed With Wild-Type Transthyretin Cardiac Amyloidosis

A Phase 4 interventional study of Trimetazidine and Placebo in Transthyretin Amyloid Cardiopathy and Mitochondrial Pathology, sponsored by Steen Hvitfeldt Poulsen. Completed at 1 site in Denmark. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2024-04-25.

Sponsored by Steen Hvitfeldt Poulsen · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Study summary

Wild-type transthyretin cardiac amyloidosis (ATTRwt) is a deposition disorder in which one of the proteins of the body misfolds and accumulates at various places in the body, including the heart, leading to both mechanical and cellular damage. The gradual development of the disease will ultimately lead to heart failure and death

The protein which deposits in the heart of patients, damages both the heart mechanically as the myocardium becomes rigid and hypertrophic over time but also at the cellular level. Cell damage can be observed by elevated blood tests for cell damage (Troponin) and during exercise tests that show patients' hearts burning oxygen inefficiently when exposed to physical stress compared with the hearts of healthy individuals . No one has, however, intimately studied this cellular damage.

Vastarel® (Trimetazidine, TMZ) is an already known drug for the treatment of chest pain. The mechanism of action indicates that it may have an effect on patients with cardiac amyloidosis.

The study aims to investigate the effects of TMZ on the mitochondrial function, myocardial performance, and invasive hemodynamics in patients with ATTRwt with a randomized, double-blinded, crossover-trial.

02

Conditions studied

  • Transthyretin Amyloid Cardiopathy
  • Mitochondrial Pathology
03

In context

Lead sponsor

Steen Hvitfeldt Poulsen is the lead sponsor of 10 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Wild-type transthyretin cardiac amyloidosis
  • NAC stage I
  • class of I or II

Exclusion criteria

Exclusion Criteria:

  • Other, similar diagnoses
  • Hereditary transthyretin cardiac amyloidosis
  • Light chain amyloidosis
  • Morbus Waldenstrøm
  • Myelomatosis
  • Medical treatment with loop diuretics in standard doses (40 mgx1 daily)
  • to trimetazidine
  • Significant comorbidity assessed by the investigators
  • Unable to provide
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Active comparator
    Active Drug

    Study participants receiving Trimetazidine

    Drug: Trimetazidine

  • Placebo comparator
    Placebo

    Study participants receiving placebo (calcium)

    Drug: Placebo

Interventions

  • Oral intake of capsules

  • DrugPlacebo

    Oral intake of capsules

06

What researchers measure

Primary outcomes

  1. Change: pulmonary capillary wedge pressure (PCWP)

    We hypothesize a change in PCWP of 5 mmHg between the active drug and placebo using right heart catheterization.

    Time frame: Four weeks of treatment

Secondary outcomes

  1. Change: cardiac index (CI)

    We hypothesize a change in CI of 0.5 L/min between the active drug and placebo using right heart catheterization.

    Time frame: Four weeks of treatment

07

Study locations

1 site
  • Aarhus University Hospital, Department of Cardiology
    Aarhus N, Danmark 8200, Denmark
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Jun 2023, 20 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2021
First posted
Dec 1, 2022
StartActual
Oct 1, 2021
Primary completionActual
Jun 1, 2023
CompletionActual
Jun 1, 2023
Last update
Apr 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05633563
Lead sponsor
Steen Hvitfeldt Poulsen
Responsible party
Steen Hvitfeldt Poulsen (Professor, PhD, DMSci, Aarhus University Hospital Skejby) — Sponsor-investigator
First posted
Dec 1, 2022
Start date
Oct 1, 2021
Primary completion
Jun 1, 2023
Completion
Jun 1, 2023
Last update
Apr 25, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trimetazidine

Start the discussion